Işık Ferhat, Soner Serdar
Department of Cardiology, University of Health Sciences, Gazi Yaşargil Training and Research Hospital, Diyarbakır, TUR.
Cureus. 2022 Jul 14;14(7):e26833. doi: 10.7759/cureus.26833. eCollection 2022 Jul.
Despite effective interventional treatments, the mortality of acute ST-segment elevation myocardial infarction (STEMI) is still high. Several mortality predictors are known in STEMI. Platelet-to-hemoglobin ratio (PHR) is a recently used mortality parameter in cardiac or non-cardiac diseases. We aim to investigate the relationship of PHR with in-hospital mortality in patients with STEMI.
Eight hundred eighty-four patients were included in the study. All of them underwent coronary intervention due to STEMI. Demographic characteristics, laboratory, electrocardiographic and echocardiographic parameters were analyzed from hospital records. A cut-off value for PHR was determined using receiver operating characteristic (ROC) curve analysis. Then, patients were divided into two groups PHR < 1.99 and PHR ≥ 1.99. The data of both groups were compared.
The median age of the study population was 64 (54-75). Of these 633 (71.6 %) were male and 251 (28.4 %) were female. All cause mortality of the study population was 9.7% (n=86). In multivariable logistic regression analysis, PHR was independently associated with a significantly increased risk of in-hospital mortality for STEMI (OR: 2.645, CI: 1.641-4.263, p< 0.001). Also, age (OR: 1.044, CI: 1.021-1.067, p< 0.001), mean arterial pressure (MAP) less than 87 mmHg (OR: 2.078, CI: 1.185-3.645, p= 0.011), prior coronary artery disease (CAD) (OR: 2.839, CI: 1.345-5.993, p= 0.006), anterior myocardial infarction (MI) (OR: 1.912, CI: 1.069-3.421, p= 0.029), creatinine (OR: 3.710, CI: 2.255-6.106, p<0.001), alanine transaminase (ALT) (OR: 1.004, CI: 1.001-1.007, p=0.002), and neutrophil-to-lymphocyte ratio (NLR) (OR: 1.122, CI: 1.014-1.242, p= 0.025) were determined as independent predictors of in-hospital mortality.
In conclusion, we found that PHR is an independent predictor of in-hospital mortality in patients with STEMI.
尽管有有效的介入治疗方法，但急性ST段抬高型心肌梗死（STEMI）的死亡率仍然很高。STEMI有几个已知的死亡预测因素。血小板与血红蛋白比值（PHR）是最近在心脏或非心脏疾病中使用的死亡参数。我们旨在研究PHR与STEMI患者院内死亡率之间的关系。
本研究纳入了884例患者。他们均因STEMI接受了冠状动脉介入治疗。从医院记录中分析人口统计学特征、实验室、心电图和超声心动图参数。使用受试者工作特征（ROC）曲线分析确定PHR的临界值。然后，将患者分为两组，PHR < 1.99和PHR≥1.99。比较两组的数据。
研究人群的中位年龄为64岁（54 - 75岁）。其中633例（71.6%）为男性，251例（28.4%）为女性。研究人群的全因死亡率为9.7%（n = 86）。在多变量逻辑回归分析中，PHR与STEMI患者院内死亡风险显著增加独立相关（OR：2.645，CI：1.641 - 4.263，p < 0.001）。此外，年龄（OR：1.044，CI：1.021 - 1.067，p < 0.001）、平均动脉压（MAP）低于87 mmHg（OR：2.078，CI：1.185 - 3.645，p = 0.011）、既往冠状动脉疾病（CAD）（OR：2.839，CI：1.345 - 5.993，p = 0.006）、前壁心肌梗死（MI）（OR：1.912，CI：1.069 - 3.421，p = 0.029）、肌酐（OR：3.710，CI：2.255 - 6.106，p < 0.001）、丙氨酸转氨酶（ALT）（OR：1.004，CI：1.001 - 1.007，p = 0.002）和中性粒细胞与淋巴细胞比值（NLR）（OR：1.122，CI：1.014 - 1.242，p = 0.025）被确定为院内死亡的独立预测因素。
总之，我们发现PHR是STEMI患者院内死亡的独立预测因素。
